Home » BLOG » Valeant Pharmaceuticals International Inc under investigation by U.S. SEC

Valeant Pharmaceuticals International Inc under investigation by U.S. SEC

Valeant's head office in Laval, Quebec. The drugmaker's stock was already down about 10 per cent on Monday, after Valeant said it would withdraw its financial forecast and will delay releasing fourth-quarter results.

Valeant Pharmaceuticals International Inc. is under investigation through the U.S. Filing in a previously undisclosed probe, the organization said on Monday, capping a tumultuous 24-hour period that saw the firm announce the return of its CEO and also the cancellation of an earnings announcement.

The SEC probe is outside of an existing investigation right into a company purchased by Valeant this past year, Salix Pharmaceuticals Ltd., said a person acquainted with the matter. The person declined to discuss the record since the matter isn’t yet public.

It’s unclear what the new probe is centered around.

“Valeant confirms that it has several ongoing investigations, including investigations through the U.S. Attorney’s Offices for Massachusetts and the Southern District of recent York, the SEC, and Congress,” said Laurie Little, a Valeant spokeswoman.

Judy Burns, an SEC spokeswoman, declined to discuss the new probe.

Related

About privatefinancetips

x

Check Also

U.S. job growth slows and profits tumble as a strong dollar and cheap oil undercut earnings

WASHINGTON – U.S. economic growth slowed within the fourth quarter, although not as sharply as ...

The REIT sector’s next challenge: CEO succession and board renewal

Getting there C with new chief executives and groups of new directors for that firms ...

Commodities could be headed for ‘buffalo jump’ as investors rush for the exits, Barclays warns

Commodities including oil and copper are in chance of steep declines as recent advances aren’t ...